NPT200-11

Research use only, not for human use.

NPT200-11 is an orally bioavailable and brain penetrating inhibitor of accumulation of alpha-synuclein (ASYN) misfolding and aggregation.

NPT200-11 is an orally bioavailable and brain penetrating inhibitor of accumulation of alpha-synuclein (ASYN) misfolding and aggregation. NPT200-11 can be used in studies about the underlying pathology of synucleinopathies including Parkinson's disease (PD), dementia with Lewy bodies (DLB) and Multiple Systems Atrophy (MSA).(In Vivo):In the Line 61 transgenic mouse model overexpressing human wild type ASYN, NPT200-11 (5 mg/kg; i.p.) results in a time-dependent and progressive reduction in retinal ASYN pathology. NPT200-11 reduced alpha-synuclein pathology in cortex, reduced associated neuroinflammation (astrogliosis), normalized striatal levels of the dopamine transporter (DAT) and improved motor function.

——

——

——

Others

Other Targets

——

——

——

2227057-23-8

——

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years